Larimar Therapeutics shares key biomarker data, aims for accelerated approval for Friedreich’s ataxia drug
Larimar Therapeutics announced Monday that its Friedreich’s ataxia treatment increased median levels of a key protein called frataxin in a mid-stage study.
The biotech is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.